Navigation Links
Kidney Failure after Non-Kidney Transplants

Doctors have long known that kidney failure is a complication of organ transplantation. Now, they know more about //which types of transplants are most likely to lead to chronic kidney failure. Researchers from the University of Michigan, Ann Arbor, report patients who have intestine transplants are more likely to have kidney failure compared to those who receive heart-lung transplants.

Doctors studied more than 11,000 patients who received transplants. Of these patients, nearly 29 percent eventually required maintenance dialysis or a kidney transplant. The risk of kidney failure differed according to the type of transplant originally received. Nearly 7 percent of heart-lung transplant patients developed kidney failure, while nearly 22 percent of intestine transplant patients suffered from it. Researchers say older patients are more likely to have complications than younger patients.

Researchers write, "The risk of chronic renal failure and the need for long-term renal-replacement therapy will increase further, given the trend toward increasing longevity in the overall population of recipients of non-renal transplants, which currently numbers more than 100,000." Patients with high blood pressure, diabetes, or preexisting hepatitis C were more likely to have renal failure.

In this study, researchers say chronic kidney failure was associated with an increased risk of death by a factor of more than four. They say this alarming finding points to the need for doctors to educate patients on the high risk of kidney failure following non-renal transplant surgery.
'"/>




Page: 1

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Kidney Stones - Interesting New Research implicates bacteria as its cause
3. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
4. New Dietary Approach To Manage Kidney Stones
5. Kidney cancer on the rise
6. Kidney function can be affected by lead exposure
7. Kidney Patients Risk Heart Attacks
8. Kidney Patients Risk Heart Attacks
9. Urine Test for Kidney Cancer
10. New Hope for Kidney Failure
11. Hope for Patients With Kidney Failure
Post Your Comments:
(Date:7/25/2008)...e/ -- Klafter & Olsen LLP has filed a,class action...re" or the,"Company") (Nasdaq: ARTC ) and certain...e Western District of Texas on behalf of all perso...roCare from January 24, 2008,through July 18, 2008...ll,persons or entities who purchased call options ...
(Date:7/25/2008)...iretroviral therapy may be due to genetic factors ...A new study challenges the long-held belief that t...em,s ability to restore itself after HIV patients ...apy (HAART). , From 50 percent to 90 percent of...V. Intravenous drug use is the main cause of both ...
(Date:7/25/2008)...- BeaconEquity.com announces the,availability of T...rs can view all of the daily trading notes for fre...,s Trade Alerts include: DUSA Pharmaceuticals Inc..... (Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), A...daq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., J...
(Date:7/25/2008)...gnificant Improvements in Members, Health, ATLANT...er in health,care quality management solutions for...s entered into a long-term agreement with Wellmark...tion on Quality(SM) Incent and,Reward Best Practic...d,primary care clinicians to promote improved qual...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...a common fear in women that their sexual performan..., an international journal of obstetrics and gynec...irth affects a woman's sexual function in the long... women who had given birth for the first time. The...
...inia Tech researcher Stefan Duma has been named as...rs for his biomechanics innovations.// Technology...mechanical engineering and founding director of th...ury Biomechanics, to the 2006 'TR35' list of the t...
... publisher John Wiley & Sons, Inc., confirms their...AASLD for providing subscriptions of their journal...c., had announced on the 6th of September their pl... American Society for Paediatric Gastroenterology,...
...chers at St. Louis Children's Hospital and Washing...e requested authorities not to allow children unde...ATVs). This call was issued after a 10-year review...perience or training in driving motorized vehicles...
Other Medicine News:Health News:A young scientist recognized for biomechanics innovations 2Health News:A young scientist recognized for biomechanics innovations 3Health News:Call To Ban Use Of ATVs By Children 2
(Date:7/23/2008)...ewswire/ -- The following was,released by the U.S....g Member Smith, and Members of the Committee.,Than...e I appeared before this Committee almost six mont...the talented and dedicated professionals,at the Ju...have come to,appreciate that much more deeply thei...
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Study finds recent trend of growing US disparities in health not inevitable 12680 1Study finds recent trend of growing US disparities in health not inevitable 12680 2Study finds recent trend of growing US disparities in health not inevitable 12680 3Krill discovered living in the Antarctic abyss 2314 1Krill discovered living in the Antarctic abyss 2314 2Pharsight to Present at eClinical Forum 12678 1Pharsight to Present at eClinical Forum 12678 2HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 1HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 2HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 3HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 4HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 5HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 6HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 7HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 8HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 9HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 10HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 11HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 12HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 13HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 14HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 15HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 16HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 17HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 18HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 19HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 20HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 21HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 22
...nspire,Pharmaceuticals, Inc. (NASDAQ: ISPH) today ...al trial comparing epinastine nasal,spray and plac...or,the primary endpoint of improvement in total na...ved in the trial, with the higher,dose (0.1%) achi...ty L. Shaffer, Ph.D., Inspire,s President and CEO,...
...tCall/ -- ISTA,Pharmaceuticals, Inc., today announ....S. Phase II/III clinical study of bepotastine for...dy evaluated two,concentrations of bepotastine, ea...ndpoints of the study were the assessment of,effic... redness.,The preliminary results of the study dem...
Other Medicine Technology:Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 2ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 3ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 4ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 5
Angled for temporal approach. Solid 14 mm blades. Dull finish.
Solid 8 mm blades. Dull finish. Most popular size or model.
Closed wire 5 mm blade with a wing tip twist giving the surgeon better on-axis accessibility.
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish.
Medicine Products: